Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

By de Jonge M.J.A.   Droz J.P.   Paz-Ares L.   van Oosterom A.T.   de Wit R.   Chollet P.   Baron B.   Lacombe D.   Mettinger K.   Fumoleau P.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 329-333

Springer Publishing Company

Access to resources Recommend Favorite

The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium

By Nimeiri Halla   Singh Deepti   Kasza Kristen   Taber David   Ansari Rafat   Vokes Everett   Kindler Hedy  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 854-858

Springer Publishing Company

Access to resources Recommend Favorite

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

By Kindler Hedy   Avadhani Anjali   Wade-Oliver Kurombi   Karrison Theodore   Mani Sridhar   Vokes Everett  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 323-327

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

By Adelstein David  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1684-1689

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

By Galsky Matthew   Mironov Svetlana   Iasonos Alexia   Scattergood Joseph   Boyle Mary   Bajorin Dean  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 265-270

Springer Publishing Company

Access to resources Recommend Favorite